or patients undergoing elective surgery, the most common cause of significant morbidity and mortality is occurrence of complications related to cardiac disease. It is estimated that approximately one million patients undergoing surgery each year in the USA suffer a perioperative myocardial infarction. This is particularly true for those with previous coronary disease and those facing higher risk surgery. Because of this fact, a great deal of research has focused on assessing cardiac risk before elective surgery. Less attention has been paid to methods of modifying the risk of cardiac complications attending surgery through medication use or other strategies. The risk of cardiac complications engenders a sense of conflict in that the patient perceives surgery as a threatening foe to be overcome: the patient versus the procedure. We would like to change that paradigm, and encourage an appreciation for the risk inherent to the patient, rather than to the procedure itself. That is, preoperative evaluation of the patient’s risk, versus the procedure’s risk.

During the past 10–20 years, the assessment of cardiac risk before surgery evolved a great deal. Initially, the focus was on appropriate identification of surgical procedures that carried high risk. The focus then shifted to identifying those patient factors associated with increased risk of cardiac complications during surgery. Several technical advances were made during this time, including the introduction of imaging stress tests to assess cardiac ischaemia, such as dobutamine echocardiogram, dobutamine thallium, and adenosine or dipyridamole thallium testing. All of these modalities have been shown to identify patients at increased risk for cardiac complications of surgery. Cardiac catheterisation has also been used as a screening modality before elective surgery, though this has not been shown to be cost effective, especially given the low overall incidence of severe coronary artery disease. Studies performed during this time period also delineated the clinical factors that identify patients at increased risk of cardiac complications. More recently, efforts have been made to combine both clinical evaluation and testing in the most efficient and appropriate manner to identify patients at risk of cardiac complications. Finally, recent studies have addressed the effectiveness of medications or interventions to decrease risk in high risk patients.

Preoperative cardiac evaluation has several goals:

- evaluate and assess perioperative cardiac risk, and provide this information to both patient and surgeon for decision making purposes
- optimise appropriateness of preoperative testing and/or intervention
- to the extent possible, adjust care in order to decrease operative risk
- given the prevalence of coronary disease and its complications, assess and intervene to modify long term risks for cardiovascular disease.

We discuss below the current state of preoperative cardiac evaluation and interventions to decrease perioperative cardiac risk, and offer an approach to the preoperative assessment and perioperative care of patients with cardiac disease, focusing on risk reduction.

**CLINICAL EVALUATION**

Historically, the preoperative assessment of patients before elective surgery was based almost entirely on the clinical evaluation and examination. The American Society of Anesthesiology has used the ASA physical status classification system (1963) to grade perioperative risk. This classification could identify those at extremely high risk of complications from surgery, but did not offer much sensitivity in assessing patients’ risk. The patients in level IV or V were at extremely elevated risk, but patients categorised in level III constituted a very wide spectrum of risk and comorbid disease. Furthermore, the ASA classification system does not focus on cardiac risk per se. It offers no consideration for the presence or absence of serious coronary disease in otherwise asymptomatic or undiagnosed patients.

Lee Goldman, then a resident at Massachusetts General Hospital, conducted a study that identified clinical factors conferring elevated risk of surgical complications. By performing a
NON-INVASIVE TESTING

The introduction of sensitive non-invasive tests for coronary artery disease, particularly pharmacologic stress tests that require no treadmill exercise, has greatly influenced the preoperative assessment of cardiac risk. Several early studies demonstrated a very high sensitivity of these tests for identifying patients at increased risk of perioperative cardiac complications. Most impressively, these results have been repeatedly duplicated by a large number of investigators. In an important work on the subject, Boucher and others demonstrated that thallium testing before elective vascular surgery accurately identified those patients who suffered cardiac complications of surgery. Furthermore, those patients with a normal thallium study had a very low incidence of cardiac complications. This was followed by several other studies, which demonstrated essentially similar results. Taken together, the clinical studies of thallium testing before vascular surgery have shown strikingly consistent results. These are a very high sensitivity (between 85–100%), but a fairly low specificity for the identification of patients who suffer cardiac complications of surgery. For this reason, the negative predictive value of thallium is quite high, better than 95%, even combining all current clinical studies. The positive predictive value, however, is quite low because of the low specificity (a problem of false positive tests in lower risk patients). This makes thallium stress testing a reassuring test when negative, but clinically confusing when positive. Such results highlight the fact that thallium testing is inappropriate as a uniform screening test, particularly when applied to “low risk” individuals.

Fewer studies have examined dobutamine echocardiogram as a preoperative screening modality; however, the results are quite similar to those found with thallium testing. There is similar sensitivity with the same problem of relatively low specificity. At institutions that have established proficiency at dobutamine echocardiogram testing, the results are considered interchangeable with thallium testing. Dobutamine echocardiography has the advantage of providing information regarding valvar structure and function.

Exercise tolerance testing, without cardiac imaging, also has an important role in screening for cardiac risk. Exercise tolerance, combined with electrocardiographic interpretation (assuming a normal baseline ECG), has great prognostic power for the patient with known or suspected coronary disease. Similarly, the ability to achieve maximum predicted heart rate without ECG confers a low risk for cardiac complications of elective surgery. Because it evaluates exercise tolerance and gives an idea of the level of stress that may induce inducible ischaemia, exercise testing is generally preferable to pharmacologic testing, particularly for long term prognostication.

Because of the relatively non-specific nature of functional testing, it is best employed as a component of an organised programme for cardiac risk evaluation. Proper clinical assessment of pre-test probability of significant coronary disease will allow more prudent use and interpretation of ischaemia testing.

Invasive testing has been proposed as a screening modality for patients undergoing high risk surgery—for example, peripheral vascular reconstructions. Hertzler and colleagues reported from the Cleveland Clinic on the use of routine catheterisation on 1000 consecutive patients scheduled for vascular surgery. Although they reported a high incidence of patients with severe coronary disease, requiring coronary bypass grafting, subsequent review of the data suggests that most of those patients with coronary disease sufficiently severe to warrant revascularisation could be identified on clinical grounds. This, and the expense and risk of routine catheterisation, have led most to consider clinical and functional assessment as initial screening for cardiac risk.
METHODS FOR LOWERING PERIOPERATIVE CARDIAC RISK

Coronary bypass surgery

Recently, attention has turned to evaluating the effectiveness of methods for intervening to lower risk of cardiac complications during elective surgery. Coronary revascularisation is one such intervention. A retrospective review by Eagle and colleagues of the CASS (coronary artery surgery study) registry data supports such a protective effect. These data demonstrate that patients undergoing elective vascular surgery, who had previously undergone coronary artery bypass grafting, did better than control patients who had similar amounts of coronary disease, but no surgical coronary revascularisation. This type of analysis does not take into consideration the cumulative risk of both coronary and peripheral revascularisation, and so does not necessarily argue for prophylactic surgical coronary revascularisation before elective peripheral vascular surgery. But it does suggest a protective effect of prior coronary bypass surgery. Data from the Cleveland Clinic showed similar findings—that patients with a history of coronary artery bypass grafting, regardless of clinical risk factors, had lower perioperative cardiac complication rates surrounding vascular surgery than patients with coronary disease managed medically. These studies argue that a history of successful coronary artery bypass surgery confers a lower risk of cardiac complications surrounding elective surgery.

Percutaneous coronary intervention

The discovery of ischaemia on functional testing frequently leads to consideration of percutaneous revascularisation before elective vascular surgery. This practice has not been subjected to randomised controlled trials to assess its efficacy. Trials are currently underway for this purpose. Previous randomised studies comparing medical treatment with angioplasty in patients with stable coronary disease of limited severity have demonstrated an increased event rate in those patients undergoing angioplasty. The bulk of this increase came in the form of periprocedural complications. Retrospective studies reporting the rates of perioperative cardiac complications in patients who underwent previous preoperative angioplasty and/or coronary stent placement have shown very mixed results. Posner and colleagues reported a lower rate of cardiac complications among patients who underwent angioplasty before surgery compared with a group of patients with coronary artery disease managed medically.

This study is uncontrolled for severity of disease or medical management, however. Massie and associates performed a case–control study comparing patients with abnormal thallium studies who did and did not undergo angiography before vascular surgery, and found no difference in event rates. Hassan and colleagues found similarly low rates of cardiac complications after non-cardiac surgery among patients in the BARI (bypass angioplasty revascularization investigation) study. This was equally true for patients who had undergone multivessel percutaneous coronary intervention, as for those who underwent coronary bypass surgery. Finally, Kaluza and colleagues reported a very high incidence of stent thrombosis, death, and myocardial infarction in patients undergoing non-cardiac surgery within two weeks of coronary stent placement. These data raise concern that the strategy of prophylactic, percutaneous coronary revascularisation before elective surgery may result in destabilisation of previously stable coronary disease which offsets the potential advantage of improving ischaemic thresholds of the heart by reducing severe, fixed coronary stenoses.

Perioperative medical treatment

Several recent studies have suggested that β blockers decrease risk of perioperative complications. A randomised study by Mangano and colleagues evaluated brief courses of perioperative β blockade in patients undergoing a variety of surgical procedures. The study was small, and demonstrated no difference in perioperative complication rate. However, over the succeeding two years, the patients who received this brief course of perioperative β blockade had a lower incidence of cardiac events. This study did not control for medications between the two groups, but at least raises the question of a protective effect of perioperative β blockade. A more recent study by Poldermans and associates randomised only clinically high risk patients undergoing elective, major vascular surgery, to the β blocker bucindolol or placebo. This study demonstrated a significant reduction in perioperative cardiac events, both fatal and non-fatal, with the use of a β blocker. These patients were given β blocker treatment days or weeks before surgery. The β blocker was titrated to a target dose of 10 mg per day, so long as the heart rate remained above 60 beats per minute. These studies, combined with previous investigations that show a protective effect of β blockers for both ambulatory and perioperative ischaemia, support the hypothesis that perioperative β blockade decreases cardiac risk among high risk patients.

Finally, several recent studies evaluated the effect of α receptor agonists in the perioperative period on the incidence of cardiac events. In a large randomised controlled trial of intravenous αs agonist mivazerol during surgery, Oliver and colleagues compared outcomes during surgery in patients who had either a history of coronary artery disease, or the presence of significant risk factors. They found no significant effect in the patients undergoing non-cardiac surgery in general, but a significant reduction in both cardiac events and death in the subset of patients undergoing vascular surgery. Mangano and colleagues reported the results of a randomised trial of the same agent in 300 patients undergoing non-cardiac surgery, and found no significant effect on cardiac events. These and other studies at least raise the possibility that intraperioperative α agonists may reduce perioperative cardiac events.

These reports certainly raise hope for therapeutic intervention to lower perioperative risk of cardiac events. The initial β blocker study of Poldermans and colleagues demonstrated benefit in a high risk cohort of patients undergoing vascular surgery. More recent data from the same group suggests benefit from β blockade across all risk groups. This requires prospective trial validation. Currently, it seems quite reasonable to use the American College of Cardiology/American Heart Association (ACC/AHA) guidelines to assess risk, and consider β blockade in any patients at increased risk not already taking them. The role of α agonists is less clear. The above mentioned studies suggest some benefit from their use in patients undergoing vascular surgery, but little is known about these patients, and what the indications for use of this agent would be.

PUTTING IT ALL TOGETHER

The past two decades have answered many questions about perioperative cardiac complications, and who is at increased risk for them. As discussed above, we have a good understanding of what constitutes a high risk patient, and what tests are useful in further defining risk. The ACC/AHA preoperative evaluation guidelines describe a method of integrating these data into an efficient, evidence based approach to evaluating cardiac risk. This approach incorporates three
Clinical evaluation steps
(1) Emergency surgery
(2) Prior coronary revascularisation
(3) Prior coronary evaluation
(4) Clinical markers of risk?
(5) Functional capacity?
(6) Surgery specific risks?

1. Need for non-cardiac surgery
   - Urgent
   - Elective

2. Coronary revascularisation within 5 years
   - If yes, and no recurrent symptoms
   - Surgery

3. Recent coronary evaluation
   - YES
   - Favourable findings
     - Adequate test
     - Review if possible
   - NO

   - Major clinical predictors (A)
     - Delay or cancel surgery
     - Cardiac catheterisation
     - Intermediate (>2) clinical predictors
     - Minor or no clinical predictors

4. Clinical assessment (Hx MI, CHF, DM, angina, age > 70)
   - Poor <4 METs
   - Moderate to excellent ≥4 METs

5. Functional capacity (B)
   - High risk
   - Intermediate risk
   - Low risk
   - High risk
   - Intermediate risk or low risk

6. Surgical risk category (C)
   - Non-invasive testing
   - Operating room

A. Major clinical predictors of increased cardiovascular risk
- Unstable coronary syndromes
- Recent myocardial infarction with evidence of important ischaemic risk by clinical symptoms or non-invasive study
- Unstable or severe angina (Canadian Cardiovascular Society class III or IV)
- Decompensated heart failure
- Significant arrhythmias
- High grade ventricular arrhythmias in the presence of underlying heart disease
- Supraventricular arrhythmias with uncontrolled ventricular rate
- Severe valvar disease

Figure 1 Algorithm for cardiac risk assessment before non-cardiac surgery. Hx MI, history of myocardial infarction; CHF, congestive heart failure; DM, diabetes mellitus.
cardiac catheterisation should be considered), or if any of the five clinical markers of risk are present (history of myocardial infarction, diabetes mellitus, congestive heart failure, angina, age > 70 years). A decision about stress testing is based on the clinical markers of risk present, the patient's functional capacity by history, and the expected cardiovascular stress posed by non-cardiac surgery (fig 1).

In this way, a systematic approach, based on the current literature and validated prediction tools, can guide the assessment of risk, and the prudent use of further diagnostic testing of cardiac risk before non-cardiac surgery. As stated above, this systematic approach does not rely on testing, but incorporates clinical evaluation with objective testing to define cardiac risk of non-cardiac surgery optimally.

B. Estimated functional capacity, based on daily activities

1 MET
- Can you take care of yourself?
- Eat, dress or use the toilet?
- Walk indoors around the house?
- Walk a block or two on level ground at 2–3 mph or 3.2–4.8 km/h?
- Do light work around the house like dusting or washing dishes?

4 METs
- Climb a flight of stairs or walk up a hill?
- Walk on level ground at 4 mph or 6.4 km/h?
- Run a short distance?
- Do heavy work around the house like scrubbing floors or lifting or moving heavy furniture?
- Participate in moderate recreational activities like golf, bowling, dancing, doubles tennis, or throwing a baseball or football?
- Participate in strenuous sports like swimming, singles tennis, football, basketball, or skiing?

>10 METs
- Participate in strenuous activities like participating in heavy work around the house, or strenuous sports like swimming, singles tennis, football, basketball, or skiing?
- Do you perform moderate exercise?

C. Risk stratification for non-cardiac surgical procedures

Major (reported cardiac risk often > 5%)
- Emergent major operations, particularly in the elderly
- Aortic and other major vascular
- Peripheral vascular
- Anticipated prolonged surgical procedures associated with large fluid shifts and/or blood loss

Intermediate (reported cardiac risk 1–5%)
- Carotid endarterectomy
- Head and neck
- Intraperitoneal and intrathoracic
- Orthopaedic
- Prostate

Low* (reported cardiac risk generally < 1%)
- Endoscopic procedures
- Superficial procedure
- Cataract
- Breast

*Do not generally require further preoperative cardiac testing

Key points

- Exploit opportunity of preoperative evaluation to assess and intervene upon reversible cardiovascular risk factors
- Evaluation based on cardiac risk, not pending surgery
- Utilise history, physical, and ECG findings to stratify clinical risk
- Further evaluation (for example, stress testing, catheterisation), based on clinical evaluation, and probability of disease
- Use stress testing to modify, not co-opt, pre-testing likelihood of disease
- Decision regarding stress testing, cardiac catheterisation, or revascularisation, based on algorithm
- β Blockade indicated for higher risk patients undergoing vascular surgery.

REFERENCES

- Excellent review of the topic.
- Seminal work, identifying for the first time the magnitude and nature of the impact on perioperative cardiac risk of several important clinical findings.
- This study shows the relative roles of clinical and radiological evaluation of patients before vascular surgery, and the value of combining the two to improve accuracy and decrease testing.
- Confirmatory study, documenting the power of clinical risk factors to predict severity of coronary disease.
- Early, single centre report of findings on routine cardiac catheterisation in patients undergoing vascular surgery.
- Confirms a clinical observation.
- Shows a significant risk associated with stopping antiplatelet agents within 2–4 weeks of PCI.
- BARI study data suggesting low rate of cardiac events after either coronary bypass surgery or multi-vessel coronary angioplasty before non-cardiac surgery.
- BARI study data suggesting low rate of cardiac events after either coronary bypass surgery or multi-vessel coronary angioplasty before non-cardiac surgery.
- One of few studies looking at the important question of timing of surgery after percutaneous coronary intervention (PCI). This study suggests significant risk associated with stopping antiplatelet agents within 2–4 weeks of PCI.


Current ACC/AHA guidelines for cardiac evaluation prior to non-cardiac surgery. Contains a very thorough review of the entire English language literature.
Anaesthesia and the cardiac patient: the patient versus the procedure

James B Froehlich and Kim A Eagle

*Heart* 2002 87: 91-96
doi: 10.1136/heart.87.1.91

Updated information and services can be found at:
http://heart.bmj.com/content/87/1/91

**References**
This article cites 14 articles, 2 of which you can access for free at:
http://heart.bmj.com/content/87/1/91#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8842)
- Epidemiology (3752)
- Acute coronary syndromes (2742)
- Clinical diagnostic tests (4779)
- Echocardiography (2127)
- Interventional cardiology (2933)
- Percutaneous intervention (964)
- Education in Heart (527)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/